Radionuclide Therapy via SSTR: Future Aspects from Experimental Animal Studies
Radionuclide Therapy via SSTR: Future Aspects from Experimental Animal Studies
复制标题
DOI：
10.1159/000336086
复制
发表时间：
2013-01-01
影响因子：
4.1
通讯作者：
Ahlman, Hakan
中科院分区：
文献类型：
--
作者：
Forssell-Aronsson, Eva;Spetz, Johan;Ahlman, Hakan
神经内分泌肿瘤需要更好的治疗选择。本综述的目的是总结实验动物研究的结果，并提出未来基于生长抑素（SS）受体在许多神经内分泌肿瘤高表达的放射性核素治疗的想法。综上所述，主要选择之一是针对每位患者进行个体化治疗，包括选择SS类似物、放射性核素和治疗计划。其他选择包括增加肿瘤组织治疗效果的方法（通过上调受体表达和避免受体结合饱和来增加肿瘤摄取和保留），增加肿瘤组织反应的方法（通过选择放射性核素、SS类似物或联合治疗），以及减少副作用的方法（减少关键器官的摄取和保留，减少正常组织反应）。此外，可以考虑与其他放射性药物、细胞毒性药物或放射增敏剂联合治疗，以增强放射性标记的SS类似物的效果。巴塞尔S. Karger股份有限公司版权所有
There is need for better therapeutic options for neuroendocrine tumours. The aim of this review was to summarize results of experimental animal studies and raise ideas for future radionuclide therapy based on high expression of somatostatin (SS) receptors by many neuroendocrine tumours. In summary, one of the major options is individualized treatment for each patient, including choice of SS analogues, radionuclides and treatment schedules. Other options are methods to increase the treatment effect on tumour tissue (increasing tumour uptake and retention by upregulation of receptor expression and avoiding saturation of receptor binding), methods to increase the tumour tissue response (by choice of radionuclides, SS analogues or combined therapies), and methods to reduce side effects (diminished uptake and retention in critical organs and reduced normal tissue response). Furthermore, combination therapy with other radiopharmaceuticals, cytotoxic drugs or radiosensitizers can be considered to enhance the effects of radiolabelled SS analogues. Copyright (C) 2012 S. Karger AG, Basel